OSPREY MEDICAL INC - Announcements

0.00%

20.0¢

Currently unlisted.

Osprey Medical, Inc. is a commercial stage company, which is focused on protecting... Osprey Medical, Inc. is a commercial stage company, which is focused on protecting patients from the harmful effects of X-ray dye (contrast) used during commonly performed angiographic imaging procedures. The Company’s products include AVERT, AVERT Plus, the DyeVert NG, DyeVert Plus, and DyeVert Plus EZ Systems. The AVERT Plus System reduces and monitors the amount of contrast dye used in commonly performed heart and peripheral vascular procedures. The DyeVert System is a self-adjusting product that reduces the amount of contrast dye used in commonly performed heart and peripheral procedures. DyeVert interfaces with syringe-manifold systems. These technologies are available with the United States Food and Drug Administration cleared indication for dye volume reduction. Its dye reduction and monitoring technologies are designed to help physicians minimize dye usage and reduce kidney damage associated with the use of contrast media for common cardiovascular procedures.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

OSP	Osprey - Oversubscribed A$28 Million Private Placement-OSP.AX	PRICE SENSITIVE	04/08/16	123.62KB	Share
OSP	Trading Halt-OSP.AX	PRICE SENSITIVE	02/08/16	357.91KB	Share
OSP	Response to ASX Price Query-OSP.AX	PRICE SENSITIVE	29/07/16	500.07KB	Share
OSP	Appendix 4C - quarterly-OSP.AX	PRICE SENSITIVE	20/07/16	804.55KB	Share
OSP	Osprey Medical Inc - Q2 Key Sales Milestones-OSP.AX	PRICE SENSITIVE	07/07/16	107.78KB	Share
OSP	AVERT Trial Results Presented at SCAI-OSP.AX	PRICE SENSITIVE	09/05/16	236.14KB	Share
OSP	Appendix 4C - quarterly-OSP.AX	PRICE SENSITIVE	21/04/16	286.86KB	Share
OSP	Preliminary Final Report and Full Year Statutory Accounts	PRICE SENSITIVE	25/02/16	376.34KB	Share
OSP	Osprey Receives FDA Clearance for Key DyeVert System Claims	PRICE SENSITIVE	08/02/16	83.27KB	Share
OSP	Appendix 4C - quarterly	PRICE SENSITIVE	28/01/16	226.9KB	Share
OSP	Findings from steering committee analysis of AVERT trial	PRICE SENSITIVE	18/12/15	292.08KB	Share
OSP	Appendix 4C - quarterly	PRICE SENSITIVE	30/10/15	274.91KB	Share
OSP	AVERT Trial Results, FDA Expanded Claims Achieved, US Launch	PRICE SENSITIVE	19/10/15	178.76KB	Share
OSP	Osprey Receives DyeVert System FDA Clearance	PRICE SENSITIVE	12/10/15	79.14KB	Share
OSP	Half Year Financial Results and Revised Appendix 4D	PRICE SENSITIVE	31/08/15	665.42KB	Share
OSP	Appendix 4D and Half Year Financial Reports	PRICE SENSITIVE	31/08/15	456.69KB	Share
OSP	Appendix 4C - quarterly	PRICE SENSITIVE	30/07/15	275.07KB	Share
OSP	Osprey Completes Enrolment of AVERT IDE Clinical Study	PRICE SENSITIVE	16/07/15	74.3KB	Share
OSP	Appendix 4C	PRICE SENSITIVE	24/04/15	187.76KB	Share
OSP	Reinstatement of Official Quotation	PRICE SENSITIVE	23/03/15	63.62KB	Share
OSP	Reinstatement of Official Quotation	PRICE SENSITIVE	23/03/15	63.62KB	Share
OSP	Osprey Announces $16.3 Private Placement	PRICE SENSITIVE	23/03/15	93.72KB	Share
OSP	Osprey Announces $16.3 Private Placement	PRICE SENSITIVE	23/03/15	93.72KB	Share
OSP	Suspension from Official Quotation	PRICE SENSITIVE	19/03/15	223.57KB	Share
OSP	Trading Halt	PRICE SENSITIVE	17/03/15	196.52KB	Share
OSP	Preliminary Final Report and Full Year Financial Results	PRICE SENSITIVE	18/02/15	402.04KB	Share
OSP	Appendix 4C - quarterly	PRICE SENSITIVE	30/01/15	239.87KB	Share
OSP	AVERT Contrast Monitoring Technology Receives FDA Clearance	PRICE SENSITIVE	16/12/14	101.24KB	Share
OSP	Appendix 4C - quarterly	PRICE SENSITIVE	20/10/14	198.97KB	Share
OSP	Half Yearly Report and Accounts	PRICE SENSITIVE	22/08/14	476.85KB	Share
OSP	Physicians use AVERT in peripheral artery disease procedures	PRICE SENSITIVE	04/08/14	75.71KB	Share
OSP	Appendix 4C - quarterly	PRICE SENSITIVE	22/07/14	182.98KB	Share
OSP	US FDA Clearance for the AVERT System	PRICE SENSITIVE	17/06/14	108.33KB	Share
OSP	Appendix 4C	PRICE SENSITIVE	24/04/14	155.75KB	Share
OSP	Limb Recovery System Presented at Major Medical Conference	PRICE SENSITIVE	10/04/14	65.4KB	Share
OSP	Preliminary Final Report and Annual Financial Statements	PRICE SENSITIVE	25/02/14	441.83KB	Share
OSP	Appendix 4C - quarterly	PRICE SENSITIVE	23/01/14	88.18KB	Share
OSP	Enrolment of first patient in the AVERT IDE Clinical Study	PRICE SENSITIVE	07/01/14	81.42KB	Share
OSP	Publication of results from AVERT pilot clinical trial	PRICE SENSITIVE	02/01/14	323.06KB	Share
OSP	AVERT System U.S. Commercialization Activities	PRICE SENSITIVE	02/12/13	79.55KB	Share
OSP	Osprey Medical Names AVERT Trial Medical Leadership	PRICE SENSITIVE	18/11/13	89.96KB	Share
OSP	Osprey Commences Diabetic Limb Efficacy Study	PRICE SENSITIVE	22/10/13	66.88KB	Share
OSP	Osprey Announces A$14 million Placement	PRICE SENSITIVE	16/10/13	97.1KB	Share
OSP	Trading Halt	PRICE SENSITIVE	14/10/13	236.72KB	Share
OSP	Appendix 4C - quarterly	PRICE SENSITIVE	11/10/13	80.84KB	Share
OSP	Osprey to Commence AVERT System IDE Clinical Trial	PRICE SENSITIVE	17/09/13	81.95KB	Share
OSP	Half Yearly Report and Accounts	PRICE SENSITIVE	27/08/13	1.09MB	Share
OSP	US FDA Clearance for AVERT System	PRICE SENSITIVE	23/08/13	82.93KB	Share
OSP	Appendix 4C - quarterly	PRICE SENSITIVE	19/07/13	156.16KB	Share
OSP	Investor Newsletter - July 2013	PRICE SENSITIVE	15/07/13	4.06MB	Share
OSP	Appendix 4C - quarterly	PRICE SENSITIVE	24/04/13	145.55KB	Share
OSP	Enrolment of First Patient in CINCOR IDE Clinical Study	PRICE SENSITIVE	21/03/13	90.69KB	Share
OSP	Preliminary Final Report	PRICE SENSITIVE	26/02/13	8.02MB	Share
OSP	Appendix 4C - quarterly	PRICE SENSITIVE	29/01/13	157.66KB	Share
OSP	Enrolment of First Patient in Diabetic Limb Clinical Study	PRICE SENSITIVE	04/12/12	89.27KB	Share
OSP	Osprey enhances CINCOR System	PRICE SENSITIVE	31/10/12	387.42KB	Share
OSP	Appendix 4C - quarterly	PRICE SENSITIVE	23/10/12	337.41KB	Share
OSP	Half Yearly Report and Accounts	PRICE SENSITIVE	20/08/12	206.88KB	Share
OSP	Appendix 4C - quarterly	PRICE SENSITIVE	30/07/12	520.33KB	Share
OSP	OSP receives A$1.1 million Victorian Government Grant	PRICE SENSITIVE	04/07/12	391.45KB	Share
OSP	Admission to Official List	PRICE SENSITIVE	30/04/12	80.09KB	Share

OSP Osprey - Oversubscribed A$28 Million Private Placement-OSP.AX
04/08/16	PRICE SENSITIVE	123.62KB	Share
OSP Trading Halt-OSP.AX
02/08/16	PRICE SENSITIVE	357.91KB	Share
OSP Response to ASX Price Query-OSP.AX
29/07/16	PRICE SENSITIVE	500.07KB	Share
OSP Appendix 4C - quarterly-OSP.AX
20/07/16	PRICE SENSITIVE	804.55KB	Share
OSP Osprey Medical Inc - Q2 Key Sales Milestones-OSP.AX
07/07/16	PRICE SENSITIVE	107.78KB	Share
OSP AVERT Trial Results Presented at SCAI-OSP.AX
09/05/16	PRICE SENSITIVE	236.14KB	Share
OSP Appendix 4C - quarterly-OSP.AX
21/04/16	PRICE SENSITIVE	286.86KB	Share
OSP Preliminary Final Report and Full Year Statutory Accounts
25/02/16	PRICE SENSITIVE	376.34KB	Share
OSP Osprey Receives FDA Clearance for Key DyeVert System Claims
08/02/16	PRICE SENSITIVE	83.27KB	Share
OSP Appendix 4C - quarterly
28/01/16	PRICE SENSITIVE	226.9KB	Share
OSP Findings from steering committee analysis of AVERT trial
18/12/15	PRICE SENSITIVE	292.08KB	Share
OSP Appendix 4C - quarterly
30/10/15	PRICE SENSITIVE	274.91KB	Share
OSP AVERT Trial Results, FDA Expanded Claims Achieved, US Launch
19/10/15	PRICE SENSITIVE	178.76KB	Share
OSP Osprey Receives DyeVert System FDA Clearance
12/10/15	PRICE SENSITIVE	79.14KB	Share
OSP Half Year Financial Results and Revised Appendix 4D
31/08/15	PRICE SENSITIVE	665.42KB	Share
OSP Appendix 4D and Half Year Financial Reports
31/08/15	PRICE SENSITIVE	456.69KB	Share
OSP Appendix 4C - quarterly
30/07/15	PRICE SENSITIVE	275.07KB	Share
OSP Osprey Completes Enrolment of AVERT IDE Clinical Study
16/07/15	PRICE SENSITIVE	74.3KB	Share
OSP Appendix 4C
24/04/15	PRICE SENSITIVE	187.76KB	Share
OSP Reinstatement of Official Quotation
23/03/15	PRICE SENSITIVE	63.62KB	Share
OSPReinstatement of Official Quotation
23/03/15	PRICE SENSITIVE	63.62KB	Share
OSP Osprey Announces $16.3 Private Placement
23/03/15	PRICE SENSITIVE	93.72KB	Share
OSPOsprey Announces $16.3 Private Placement
23/03/15	PRICE SENSITIVE	93.72KB	Share
OSP Suspension from Official Quotation
19/03/15	PRICE SENSITIVE	223.57KB	Share
OSP Trading Halt
17/03/15	PRICE SENSITIVE	196.52KB	Share
OSP Preliminary Final Report and Full Year Financial Results
18/02/15	PRICE SENSITIVE	402.04KB	Share
OSP Appendix 4C - quarterly
30/01/15	PRICE SENSITIVE	239.87KB	Share
OSP AVERT Contrast Monitoring Technology Receives FDA Clearance
16/12/14	PRICE SENSITIVE	101.24KB	Share
OSP Appendix 4C - quarterly
20/10/14	PRICE SENSITIVE	198.97KB	Share
OSP Half Yearly Report and Accounts
22/08/14	PRICE SENSITIVE	476.85KB	Share
OSP Physicians use AVERT in peripheral artery disease procedures
04/08/14	PRICE SENSITIVE	75.71KB	Share
OSP Appendix 4C - quarterly
22/07/14	PRICE SENSITIVE	182.98KB	Share
OSP US FDA Clearance for the AVERT System
17/06/14	PRICE SENSITIVE	108.33KB	Share
OSPAppendix 4C
24/04/14	PRICE SENSITIVE	155.75KB	Share
OSPLimb Recovery System Presented at Major Medical Conference
10/04/14	PRICE SENSITIVE	65.4KB	Share
OSPPreliminary Final Report and Annual Financial Statements
25/02/14	PRICE SENSITIVE	441.83KB	Share
OSPAppendix 4C - quarterly
23/01/14	PRICE SENSITIVE	88.18KB	Share
OSPEnrolment of first patient in the AVERT IDE Clinical Study
07/01/14	PRICE SENSITIVE	81.42KB	Share
OSPPublication of results from AVERT pilot clinical trial
02/01/14	PRICE SENSITIVE	323.06KB	Share
OSPAVERT System U.S. Commercialization Activities
02/12/13	PRICE SENSITIVE	79.55KB	Share
OSPOsprey Medical Names AVERT Trial Medical Leadership
18/11/13	PRICE SENSITIVE	89.96KB	Share
OSPOsprey Commences Diabetic Limb Efficacy Study
22/10/13	PRICE SENSITIVE	66.88KB	Share
OSPOsprey Announces A$14 million Placement
16/10/13	PRICE SENSITIVE	97.1KB	Share
OSPTrading Halt
14/10/13	PRICE SENSITIVE	236.72KB	Share
OSPAppendix 4C - quarterly
11/10/13	PRICE SENSITIVE	80.84KB	Share
OSPOsprey to Commence AVERT System IDE Clinical Trial
17/09/13	PRICE SENSITIVE	81.95KB	Share
OSPHalf Yearly Report and Accounts
27/08/13	PRICE SENSITIVE	1.09MB	Share
OSPUS FDA Clearance for AVERT System
23/08/13	PRICE SENSITIVE	82.93KB	Share
OSPAppendix 4C - quarterly
19/07/13	PRICE SENSITIVE	156.16KB	Share
OSPInvestor Newsletter - July 2013
15/07/13	PRICE SENSITIVE	4.06MB	Share
OSPAppendix 4C - quarterly
24/04/13	PRICE SENSITIVE	145.55KB	Share
OSPEnrolment of First Patient in CINCOR IDE Clinical Study
21/03/13	PRICE SENSITIVE	90.69KB	Share
OSPPreliminary Final Report
26/02/13	PRICE SENSITIVE	8.02MB	Share
OSPAppendix 4C - quarterly
29/01/13	PRICE SENSITIVE	157.66KB	Share
OSPEnrolment of First Patient in Diabetic Limb Clinical Study
04/12/12	PRICE SENSITIVE	89.27KB	Share
OSPOsprey enhances CINCOR System
31/10/12	PRICE SENSITIVE	387.42KB	Share
OSPAppendix 4C - quarterly
23/10/12	PRICE SENSITIVE	337.41KB	Share
OSPHalf Yearly Report and Accounts
20/08/12	PRICE SENSITIVE	206.88KB	Share
OSPAppendix 4C - quarterly
30/07/12	PRICE SENSITIVE	520.33KB	Share
OSPOSP receives A$1.1 million Victorian Government Grant
04/07/12	PRICE SENSITIVE	391.45KB	Share
OSPAdmission to Official List
30/04/12	PRICE SENSITIVE	80.09KB	Share

REFRESH

First

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

OSPREY MEDICAL INC - Announcements

Corporate SpotlightNot Yet Available

Announcements

Top Stories

Corporate Spotlight
Not Yet Available